CHK1 has also been considered a promising drug target, with a number of agents in pre-clinical and clinical development for use as monotherapy or in combination with DNA damaging agents; among a number of CHK1 targeting drugs, the inhibitor prexasertib has shown particularly good efficacy across multiple cancer types [39,40]. Here, CHEK1 is linked to cancer.